Condition: Dementia, Lewy Body · Sponsor: University of Bergen
The goal of the study is to develop predictive algorithms and digital biomarkers to capture disease fluctuations in (prodromal) dementia with lewybodies (DLB) patients and to improve treatment, diagnosis and prognosis of the study drug Ambroxol, used in the ANeED study. This project is an additional study to the ANeED study, registered at ClinicalTrials.gov under NCT04588285.
This description comes directly from the study's public registry record.
Arvid Rongve, PhD · 90548749 · arvid.rongve@uib.no
Jessica Hubbers, MSc · 91692898 · jessica.hubbers@helse-fonna.no
Always discuss trial participation with your own doctor first.
| Helse Fonna | Haugesund, Rogaland, Norway | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05773443